Endosomal/Vacuolar pathway
gene
reagent
sample publication
sample review
B2M
beta-2-microglobulin
total:5
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. 2008 to the paper
Dako anti-B2m was used to perform immunohistochemistry in order to study the presence of specific populations of tumor infiltrating lymphocytes in diagnostic primary melanoma biopsies are associated with outcome in clinically stage II melanoma patients. more
cathepsin L
total:8
Anaplasma phagocytophilum increases cathepsin L activity, thereby globally influencing neutrophil function. 2008 to the paper
Calbiochem of EMD Bioscience Inc. anti-cathepsin L antibody was used in western blot to study the effect of the role for Anaplasma phagocytophilum in increasing cathepsin L activity on neutrophil function. more
CTSS
cathepsin S
total:4
T-cell activation leads to reduced collagen maturation in atherosclerotic plaques of Apoe(-/-) mice. 2009 to the paper
Abcam goat polyclonal anti-cathepsin S was used to block and incubate the blots in order to suggest that T-cell activation can limits collagen maturation in the atherosclerotic plaque. more
CTSV
cathepsin V
total:2
Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. 2006 to the paper
R&D Systems monoclonal mouse-anti-human CTSV antibody was used in immunohistochemistry to study cystatin M/E as a high affinity inhibitor of cathepsin V and cathepsin L through a reactive site that is distinct from the legumain-binding site more
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA E
major histocompatibility complex, class I, E
total:12
ESCRT-III governs the Aurora B-mediated abscission checkpoint through CHMP4C. 2012 to the paper
Serotec FITC-conjugated anti-MHC-I was used to perform flow cytometry in order to show that cell abscission mediated by Aurora B was regulated by ESCRT-III. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-F
major histocompatibility complex, class I, F
total:1
Progressive myopathy and defects in the maintenance of myotendinous junctions in mice that lack talin 1 in skeletal muscle. 2008 to the paper
Sigma mouse monoclonal MHCf antibody was used in immunohistochemistry in order to study the role of talin 1 in the development and function of skeletal muscle
oxytocinase
leucyl and cystinyl aminopeptidase
total:4
Sensing of dietary lipids by enterocytes: a new role for SR-BI/CLA-1. 2009 to the paper
ABDSerotec sheep polyclonal anti-PLAP antibody (0300-1909) was used in western blot to analyze the early events that are specifically induced by the apical supply of PPM and to determine the molecular mechanisms of PPM sensing in enterocytes. more